Floatz logo

Ipilimumab

Mesothelioma

Orion Corporation, Orion Pharmamonoclonal_antibodyPhase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

55 Active assets in the Mesothelioma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
National Cancer Institute (NCI)
Phase 2BB
Fludarabine
National Cancer Institute (NCI)
Phase 2B
Nivolumab
Orion Corporation, Orion Pharma
Phase 2B
Pembrolizumab
Genmab
Phase 2B
FLUDEOXYGLUCOSE
National Cancer Institute (NCI)
Phase 2B

View all 50 →

Same molecule, other indications

Ipilimumab is also rated in:

metastatic neoplasmDormant
BB
Indicative ·
71 / 100
View asset →
Clinical Stage IV Cutaneous Melanoma AJCC v8Dormant
BB
Indicative ·
69 / 100
View asset →
cutaneous melanomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →